Peptide hormones regulating appetite-focus on neuroimaging studies in humans

Diabetes/Metabolism Research and Reviews

Volumn 27, Issue 2, 2011, Pages 104-112

  Schloegl, Haiko ^a   Percik, Ruth ^a,b   Horstmann, Annette ^c   Villringer, Arno ^a,c   Stumvoll, Michael ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b SHEBA MEDICAL CENTER   (Israel)

^c MAX PLANCK INSTITUTE FOR HUMAN COGNITIVE AND BRAIN SCIENCES   (Germany)

Author keywords

Appetite; Gut peptides; Neuroimaging; Obesity; Regulation of eating behaviour

Indexed keywords

GHRELIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; LEPTIN; PEPTIDE YY;

APPETITE; BLOOD BRAIN BARRIER; BRAIN STEM; CALORIC INTAKE; CINGULATE GYRUS; COGNITION; CORPUS STRIATUM; ELECTROENCEPHALOGRAM; ENERGY BALANCE; EPISODIC MEMORY; FEEDING BEHAVIOR; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUSIFORM GYRUS; GASTROINTESTINAL TRACT; GUSTATORY CORTEX; HUMAN; HUNGER; HYPOTHALAMUS; INSULIN RESISTANCE; MAGNETOENCEPHALOGRAPHY; NEUROPSYCHOLOGY; OBESITY; OLFACTORY CORTEX; ORBITAL CORTEX; PLEASURE; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; REVIEW; SATIETY; SIGNAL TRANSDUCTION;

ANIMALS; APPETITE REGULATION; BRAIN; DIAGNOSTIC IMAGING; HUMANS; HUNGER; PEPTIDE HORMONES;

EID: 79551575167     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1154     Document Type: Review

References (78)

1. Chaudhri OB, Salem V, Murphy KG, Bloom SR. Gastrointestinal satiety signals. Annu Rev Physiol 2008; 70: 239-255.
2. Coll AP, Farooqi IS, O'Rahilly S. The hormonal control of food intake. Cell 2007; 129(2): 251-262.
3. Gardiner JV, Jayasena CN, Bloom SR. Gut hormones: a weight off your mind. J Neuroendocrinol 2008; 20(6): 834-841.
4. Hameed S, Dhillo WS, Bloom SR. Gut hormones and appetite control. Oral Dis 2009; 15(1): 18-26.
5. Huda MS, Wilding JP, Pinkney JH. Gut peptides and the regulation of appetite. Obes Rev 2006; 7(2): 163-182.
6. Lenard NR, Berthoud HR. Central and peripheral regulation of food intake and physical activity: pathways and genes. Obesity (Silver Spring) 2008; 16(Suppl 3): S11-S22.
7. Neary MT, Batterham RL. Gut hormones: implications for the treatment of obesity. Pharmacol Ther 2009; 124(1): 44-56.
8. Kringelbach ML. Food for thought: hedonic experience beyond homeostasis in the human brain. Neuroscience 2004; 126(4): 807-819.
9. Batterham RL, Ffytche DH, Rosenthal JM, et al. PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans. Nature 2007; 450(7166): 106-109.
10. Malik S, McGlone F, Bedrossian D, Dagher A. Ghrelin modulates brain activity in areas that control appetitive behavior. Cell Metab 2008; 7(5): 400-409.
11. Chaudhri OB, Parkinson JR, Kuo YT, et al. Differential hypothalamic neuronal activation following peripheral injection of GLP-1 and oxyntomodulin in mice detected by manganese-enhanced magnetic resonance imaging. Biochem Biophys Res Commun 2006; 350(2): 298-306.
12. Parkinson JR, Chaudhri OB, Kuo YT, et al. Differential patterns of neuronal activation in the brainstem and hypothalamus following peripheral injection of GLP-1, oxyntomodulin and lithium chloride in mice detected by manganese-enhanced magnetic resonance imaging (MEMRI). Neuroimage 2009; 44(3): 1022-1031.
13. Guthoff M, Grichisch Y, Canova C, et al. Insulin modulates food-related activity in the central nervous system. J Clin Endocrinol Metab 2010; 95(2): 748-755.
14. Farooqi IS, Bullmore E, Keogh J, Gillard J, O'Rahilly S, Fletcher PC. Leptin regulates striatal regions and human eating behavior. Science 2007; 317(5843): 1355.
15. Baicy K, London ED, Monterosso J, et al. Leptin replacement alters brain response to food cues in genetically leptin-deficient adults. Proc Natl Acad Sci U S A 2007; 104(46): 18276-18279.
16. Tataranni PA, DelParigi A. Functional neuroimaging: a new generation of human brain studies in obesity research. Obes Rev 2003; 4(4): 229-238.
17. Dozio E, Ruscica M, Motta M, Magni P. Hypothalamic neuropeptide systems as targets for potential anti-obesity drugs. Mini Rev Med Chem 2007; 7(1): 11-19.
18. de Araujo IE, Simon SA. The gustatory cortex and multisensory integration. Int J Obes (Lond) 2009; 33(Suppl 2): S34-S43.
19. Kringelbach ML, Rolls ET. The functional neuroanatomy of the human orbitofrontal cortex: evidence from neuroimaging and neuropsychology. Prog Neurobiol 2004; 72(5): 341-372.
20. O'Doherty J, Rolls ET, Francis S, Bowtell R, McGlone F. Representation of pleasant and aversive taste in the human brain. J Neurophysiol 2001; 85(3): 1315-1321.
21. Kringelbach ML, O'Doherty J, Rolls ET, Andrews C. Activation of the human orbitofrontal cortex to a liquid food stimulus is correlated with its subjective pleasantness. Cereb Cortex 2003; 13(10): 1064-1071.
22. Hare TA, Camerer CF, Rangel A. Self-control in decision-making involves modulation of the vmPFC valuation system. Science 2009; 324(5927): 646-648.
23. Heekeren HR, Wartenburger I, Marschner A, Mell T, Villringer A, Reischies FM. Role of ventral striatum in reward-based decision making. Neuroreport 2007; 18(10): 951-955.
24. Berthoud HR, Morrison C. The brain, appetite, and obesity. Annu Rev Psychol 2008; 59: 55-92.
25. Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology 2010; 35(1): 217-238.
26. Pavlov I. The Work of the Digestive Glands. Griffin: London, 1902.
27. Kamiji MM, Inui A. NPY Y2 and Y4 receptors selective ligands: promising anti-obesity drugs?. Curr Top Med Chem 2007; 7(17): 1734-1742.
28. Grandt D, Schimiczek M, Beglinger C, et al. Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36. Regul Pept 1994; 51(2): 151-159.
29. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002; 418(6898): 650-654.
30. Koda S, Date Y, Murakami N, et al. The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats. Endocrinology 2005; 146(5): 2369-2375.
31. Nonaka N, Shioda S, Niehoff ML, Banks WA. Characterization of blood-brain barrier permeability to PYY3-36 in the mouse. J Pharmacol Exp Ther 2003; 306(3): 948-953.
32. Sloth B, Davidsen L, Holst JJ, Flint A, Astrup A. Effect of subcutaneous injections of PYY1-36 and PYY3-36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese males. Am J Physiol Endocrinol Metab 2007; 293(2): E604-E609.
33. Batterham RL, Heffron H, Kapoor S, et al. Critical role for peptide YY in protein-mediated satiation and body-weight regulation. Cell Metab 2006; 4(3): 223-233.
34. Guo Y, Ma L, Enriori PJ, et al. Physiological evidence for the involvement of peptide YY in the regulation of energy homeostasis in humans. Obesity (Silver Spring) 2006; 14(9): 1562-1570.
35. Stoeckel LE, Weller RE, Giddings M, Cox JE. Peptide YY levels are associated with appetite suppression in response to long-chain fatty acids. Physiol Behav 2008; 93(1-2): 289-295.
36. le Roux CW, Batterham RL, Aylwin SJ, et al. Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology 2006; 147(1): 3-8.
37. Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349(10): 941-948.
38. DelParigi A, Chen K, Salbe AD, et al. Successful dieters have increased neural activity in cortical areas involved in the control of behavior. Int J Obes (Lond) 2007; 31(3): 440-448.
39. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402(6762): 656-660.
40. Korbonits M, Goldstone AP, Gueorguiev M, Grossman AB. Ghrelin-a hormone with multiple functions. Front Neuroendocrinol 2004; 25(1): 27-68.
41. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000; 407(6806): 908-913.
42. Date Y, Kojima M, Hosoda H, et al. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 2000; 141(11): 4255-4261.
43. Mundinger TO, Cummings DE, Taborsky GJ Jr. Direct stimulation of ghrelin secretion by sympathetic nerves. Endocrinology 2006; 147(6): 2893-2901.
44. Cummings DE, Overduin J. Gastrointestinal regulation of food intake. J Clin Invest 2007; 117(1): 13-23.
45. Kamegai J, Tamura H, Shimizu T, Ishii S, Sugihara H, Wakabayashi I. Chronic central infusion of ghrelin increases hypothalamic neuropeptide Y and agouti-related protein mRNA levels and body weight in rats. Diabetes 2001; 50(11): 2438-2443.
46. Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature 2001; 409(6817): 194-198.
47. Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001; 86(12): 5992.
48. Tolhurst G, Reimann F, Gribble FM. Nutritional regulation of glucagon-like peptide-1 secretion. J Physiol 2009; 587(Pt 1): 27-32.
49. Vilsboll T, Krarup T, Sonne J, et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 2003; 88(6): 2706-2713.
50. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87(4): 1409-1439.
51. Verdich C, Flint A, Gutzwiller JP, et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 2001; 86(9): 4382-4389.
52. Thum T, Anker SD. Liraglutide for weight loss in obese people. Lancet 2010; 375(9714): 551-552, author reply 552-553.
53. Bradley DP, Kulstad R, Schoeller DA. Exenatide and weight loss. Nutrition 2010; 26(3): 243-249.
54. Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996; 137(7): 2968-2978.
55. Hamilton A, Holscher C. Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system. Neuroreport 2009; 20(13): 1161-1166.
56. Korner M, Stockli M, Waser B, Reubi JC. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med 2007; 48(5): 736-743.
57. Deary IJ. Diabetes hypoglycemia and cognitive performance. In Handbook of Human Performance, Jones DM, Smith AP (eds). Academic Press: London, 1992; 243-259.
58. Anderson AW, Heptulla RA, Driesen N, et al. Effects of hypoglycemia on human brain activation measured with fMRI. Magn Reson Imaging 2006; 24(6): 693-697.
59. Meikle A, Riby LM, Stollery B. The impact of glucose ingestion and gluco-regulatory control on cognitive performance: a comparison of younger and middle aged adults. Hum Psychopharmacol 2004; 19(8): 523-535.
60. Levin BE, Dunn-Meynell AA, Routh VH. Brain glucose sensing and body energy homeostasis: role in obesity and diabetes. Am J Physiol 1999; 276(5 Pt 2): R1223-R1231.
61. Sandoval DA, Obici S, Seeley RJ. Targeting the CNS to treat type 2 diabetes. Nat Rev Drug Discov 2009; 8(5): 386-398.
62. Smeets PA, de Graaf C, Stafleu A, van Osch MJ, van der Grond J. Functional MRI of human hypothalamic responses following glucose ingestion. Neuroimage 2005; 24(2): 363-368.
63. Smeets PA, Vidarsdottir S, de Graaf C, et al. Oral glucose intake inhibits hypothalamic neuronal activity more effectively than glucose infusion. Am J Physiol Endocrinol Metab 2007; 293(3): E754-E758.
64. Smeets PA, de Graaf C, Stafleu A, van Osch MJ, van der Grond J. Functional magnetic resonance imaging of human hypothalamic responses to sweet taste and calories. Am J Clin Nutr 2005; 82(5): 1011-1016.
65. Gruetter R, Ugurbil K, Seaquist ER. Effect of acute hyperglycemia on visual cortical activation as measured by functional MRI. J Neurosci Res 2000; 62(2): 279-285.
66. Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL. Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 2002; 5(6): 514-516.
67. Anthony K, Reed LJ, Dunn JT, et al. Attenuation of insulin-evoked responses in brain networks controlling appetite and reward in insulin resistance: the cerebral basis for impaired control of food intake in metabolic syndrome? Diabetes 2006; 55(11): 2986-2992.
68. Tschritter O, Preissl H, Hennige AM, et al. The cerebrocortical response to hyperinsulinemia is reduced in overweight humans: a magnetoencephalographic study. Proc Natl Acad Sci U S A 2006; 103(32): 12103-12108.
69. Hallschmid M, Schultes B. Central nervous insulin resistance: a promising target in the treatment of metabolic and cognitive disorders? Diabetologia 2009; 52(11): 2264-2269.
70. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372(6505): 425-432.
71. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334(5): 292-295.
72. Boden G, Chen X, Mozzoli M, Ryan I. Effect of fasting on serum leptin in normal human subjects. J Clin Endocrinol Metab 1996; 81(9): 3419-3423.
73. Kelesidis T, Kelesidis I, Chou S, Mantzoros CS. Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med 2010; 152(2): 93-100.
74. Licinio J, Caglayan S, Ozata M, et al. Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc Natl Acad Sci U S A 2004; 101(13): 4531-4536.
75. Taubert M, Draganski B, Anwander A, et al. Dynamic properties of human brain structure: learning-related changes in cortical areas and associated fiber connections. J Neurosci 2010; 30(35): 11670-11677.
76. Matochik JA, London ED, Yildiz BO, et al. Effect of leptin replacement on brain structure in genetically leptin-deficient adults. J Clin Endocrinol Metab 2005; 90(5): 2851-2854.
77. Rosenbaum M, Sy M, Pavlovich K, Leibel RL, Hirsch J. Leptin reverses weight loss-induced changes in regional neural activity responses to visual food stimuli. J Clin Invest 2008; 118(7): 2583-2591.
78. Heymsfield SB, Greenberg AS, Fujioka K, et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999; 282(16): 1568-1575.